SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations

NASHUA, N.H., Dec. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, announced today that four novel AI-driven breast cancer research abstracts have been accepted for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), taking place from December 10-13, 2024. These clinical abstracts highlight the latest research in breast health AI, focusing on improving detection and risk prediction ...